Publications
All Chinnaiyan lab publications
Select Recent Publications:
Humble RM, Paturu R, Xiao H, Yang C, Iwata-Otsubo A, Dhanasekaran SM, Brown NA, Betz BL, Kim AS, Myers JL, Chinnaiyan AM, Shao L, Mehra R. Clinical ERG break-apart fluorescence in situ hybridization assay: practical utility and lessons from an 8-year tertiary institution experience. Am J Clin Pathol. 2026 Jan 22;165(1):aqaf128. doi: 10.1093/ajcp/aqaf128. PMID: 41370001.
Luo J, Chen Z, Qiao Y, Tien JC, Young E, Mannan R, Mahapatra S, Bhattacharyya R, Xiao L, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Rees MG, Ronan MM, Roth JA, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer. Nat Genet. 2025 Oct;57(10):2468-2481. doi: 10.1038/s41588-025-02336-6. Epub 2025 Oct 3. PMID: 41044247; PMCID: PMC12513837.
Michigan Medicine press release
Jacobs MF, Austin S, Murad AM, Koeppe E, Kumar-Sinha C, Robinson DR, Wu YM, Vo JN, Koschmann C, Robertson P, Franson A, Leung D, Chinnaiyan AM, Mody RJ. Pediatric Oncology Patients With Germline Pathogenic Variants in Adult-Onset Cancer Predisposition Genes. JCO Precis Oncol. 2025 Dec;9:e2400749. doi: 10.1200/PO-24-00749. Epub 2025 Dec 1. PMID: 41325557; PMCID: PMC12671920.
Rebernick RJ, Choi JE, Hesse C, Hosseini N, Chu A, Zhou J, Ning Y, Wang R, Cao X, Irwin M, Wu YM, Kumar C, Rabah R, Bagatell R, Chinnaiyan AM, Mody R, Cieslik M. Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma. Cell Rep Med. 2025 Oct 21;6(10):102375. doi: 10.1016/j.xcrm.2025.102375. Epub 2025 Sep 26. PMID: 41015032; PMCID: PMC12629816.
Bao Y, Chang Y, Tien JC, Cruz G, Yang F, Mannan R, Mahapatra S, Paturu R, Cao X, Su F, Wang R, Zhang Y, Gondal M, Choi JE, Gurkan JK, Miner SJ, Robinson DR, Wu YM, Zhou L, Wang Z, Kryczek I, Wang X, Cieslik M, Qiao Y, Tsodikov A, Zou W, Ding K, Chinnaiyan AM. CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models. J Clin Invest. 2025 Jul 22;135(18):e193745. doi: 10.1172/JCI193745. PMID: 40955658; PMCID: PMC12435847.
Michigan Medicine press release
Mannan R, Chen YB, Wang X, Zhang Y, Hosseini N, Sangoi AR, Acosta A, Williamson SR, Mahapatra S, Chinnaiyan AK, Hu J, Vaishampayan U, Shao L, Betz BL, Kim AS, Cao X, Su F, Wang R, Argani P, Brown N, Tickoo SK, Chinnaiyan AM, Reuter VE, Dhanasekaran SM, Mehra R. TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC). Mod Pathol. 2025 Nov;38(11):100873. doi: 10.1016/j.modpat.2025.100873. Epub 2025 Aug 25. PMID: 40865922.
Cho H, Zhang Y, Tien JC, Mannan R, Luo J, Narayanan SP, Mahapatra S, Hu J, Shelley G, Cruz G, Shahine M, Wang L, Su F, Wang R, Cao X, Dhanasekaran SM, Keller ET, Pitchiaya S, Chinnaiyan AM. Cellular cartography reveals mouse prostate organization and determinants of castration resistance. Proc Natl Acad Sci U S A. 2025 Sep 2;122(35):e2427116122. doi: 10.1073/pnas.2427116122. Epub 2025 Aug 25. PMID: 40854129; PMCID: PMC12415206.
Michigan Medicine press release
Hosseini N, Mannan R, Rebernick RJ, Su F, Wang R, Cao X, Lako A, Mellacheruvu D, Hu J, Alumkal JJ, Reichert ZR, Malik R, Mehra R, Chinnaiyan AM, Cieslik MP. Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer. Cancer Res. 2025 Nov 3;85(21):4251-4268. doi: 10.1158/0008-5472.CAN-24-3687. PMID: 40824681; PMCID: PMC12580794.
Eyunni S, Mannan R, Zhang Y, Young E, Zhang Q, Luo J, Pang M, Mahapatra S, Tien JC, George JM, Jaber M, Hakkani H, Carson SE, Todd AJ, Hosseini N, Gondal M, Rebernick RJ, Cao X, Su F, Wang R, Mehra R, Li J, Cieslik M, Chinnaiyan AM, Parolia A. Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity. Science. 2025 Sep 4;389(6764):eadv2367. doi: 10.1126/science.adv2367. Epub 2025 Sep 4. PMID: 40570057; PMCID: PMC12326538.
Michigan Medicine press release
Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2426909122. doi: 10.1073/pnas.2426909122. Epub 2025 Jun 12. PMID: 40504161; PMCID: PMC12184368.
Michigan Medicine press release
Cheng C, Hu J, Mannan R, He T, Bhattacharyya R, Magnuson B, Wisniewski JP, Peters S, Karim SA, MacLean DJ, Karabürk H, Zhang L, Rossiter NJ, Zheng Y, Xiao L, Li C, Awad D, Mahapatra S, Bao Y, Zhang Y, Cao X, Wang Z, Mehra R, Morlacchi P, Sahai V, Pasca di Magliano M, Shah YM, Weisman LS, Morton JP, Ding K, Qiao Y, Lyssiotis CA, Chinnaiyan AM. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Nature. 2025 Jun;642(8068):776-784. doi: 10.1038/s41586-025-08917-z. Epub 2025 Apr 23. PMID: 40269157; PMCID: PMC12176661.
Michigan Medicine press release
Chugh S, Tien JC, Hon J, Kenum C, Mannan R, Cheng Y, Li CC, Taher ZI, Delekta AD, Bawa PS, Apel IJ, Miner SJ, Cao X, Mehra R, Dhanasekaran SM, Qiao Y, Mody R, Chinnaiyan AM. Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma. Neoplasia. 2025 Feb;60:100964. doi: 10.1016/j.neo.2024.100964. Epub 2024 Jan 6. PMID: 39900433; PMCID: PMC11846495.
Gondal MN, Cieslik M, Chinnaiyan AM. Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients. Sci Data. 2025 Jan 22;12(1):139. doi: 10.1038/s41597-025-04381-6. PMID: 39843468; PMCID: PMC11754430.
Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L, Assani KD, Barocas DA, Ross AE, Chopra Z, Herron GC, Edelson JA, Graham NJ, Singhal U, Salami SS, Morgan TM, Palapattu GS, Wei JT, Chinnaiyan AM. Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine. J Urol. 2025 May;213(5):581-589. doi: 10.1097/JU.0000000000004421. Epub 2025 Jan 21. PMID: 39836866; PMCID: PMC11981841.
Michigan Medicine press release
Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu YM, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade. Cancer Discov. 2025 Feb 7;15(2):363-381. doi: 10.1158/2159-8290.CD-24-0435. PMID: 39540840; PMCID: PMC11803397.
Michigan Medicine press release
Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med. 2024 Oct 15;5(10):101758. doi: 10.1016/j.xcrm.2024.101758. Epub 2024 Oct 4. PMID: 39368479; PMCID: PMC11513839.
Michigan Medicine press release
Chang Y, Wang X, Yang J, Tien JC, Mannan R, Cruz G, Zhang Y, Vo JN, Magnuson B, Mahapatra S, Cho H, Dhanasekaran SM, Wang C, Wang Z, Zhou L, Zhou K, Zhou Y, Zhang P, Huang W, Xiao L, Liu WR, Hamadeh R, Su F, Wang R, Miner SJ, Cao X, Cheng Y, Mehra R, Ding K, Chinnaiyan AM. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. Cell Rep Med. 2024 Oct 15;5(10):101752. doi: 10.1016/j.xcrm.2024.101752. Epub 2024 Sep 30. PMID: 39353441; PMCID: PMC11513842.
Michigan Medicine press release
Parolia A, Eyunni S, Verma BK, Young E, Liu Y, Liu L, George J, Aras S, Das CK, Mannan R, Ur Rasool R, Mitchell-Velasquez E, Mahapatra S, Luo J, Carson SE, Xiao L, Gajjala PR, Venkatesh S, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Tien JC, Louw M, Alhusayan M, Cao X, Su F, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nat Genet. 2024 Oct;56(10):2132-2143. doi: 10.1038/s41588-024-01893-6. Epub 2024 Sep 9. PMID: 39251788; PMCID: PMC11525188.
Michigan Medicine press release
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu XS, Mannan R, Mahapatra S, Redin E, Cho H, Bao Y, Kandarpa M, Ching-Yi Tien J, Wang X, Eyunni S, Zheng Y, Kim N, Zheng H, Hou S, Su F, Miner SJ, Mehra R, Cao X, Abbineni C, Samajdar S, Ramachandra M, Dhanasekaran SM, Talpaz M, Parolia A, Rudin CM, Vakoc CR, Chinnaiyan AM. Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer Cell. 2024 Aug 12;42(8):1336-1351.e9. doi: 10.1016/j.ccell.2024.06.006. Epub 2024 Jul 18. PMID: 39029462; PMCID: PMC12147762.
Michigan Medicine press release
Choi JE, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, Gondal M, Tien JC, Maj T, Yazdani S, Parolia A, Xia H, Zhou J, Wei S, Grove S, Vatan L, Lin H, Li G, Zheng Y, Zhang Y, Cao X, Su F, Wang R, He T, Cieslik M, Green MD, Zou W, Chinnaiyan AM. PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nat Commun. 2024 Jun 28;15(1):5487. doi: 10.1038/s41467-024-48931-9. PMID: 38942798; PMCID: PMC11213953.
Mannan R, Wang X, Mahapatra S, Wang S, Chinnaiyan AK, Skala SL, Zhang Y, McMurry LM, Zelenka-Wang S, Cao X, Sangoi AR, Dadhania V, Picken MM, Menon S, Al-Ahmadie H, Chinnaiyan AM, Dhanasekaran SM, Mehra R. Expression of L1 Cell Adhesion Molecule, a Nephronal Principal Cell Marker, in Nephrogenic Adenoma. Mod Pathol. 2024 Aug;37(8):100540. doi: 10.1016/j.modpat.2024.100540. Epub 2024 Jun 18. PMID: 38901674; PMCID: PMC11344683.
Li GX, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, Petralia F, Cho H, Hosseini N, Leprevost FDV, Calinawan A, Li Y, Anand S, Dagar A, Geffen Y, Kumar-Sinha C, Chugh S, Le A, Ponce S, Guo S, Zhang C, Schnaubelt M, Al Deen NN, Chen F, Caravan W, Houston A, Hopkins A, Newton CJ, Wang X, Polasky DA, Haynes S, Yu F, Jing X, Chen S, Robles AI, Mesri M, Thiagarajan M, An E, Getz GA, Linehan WM, Hostetter G, Jewell SD, Chan DW, Wang P, Omenn GS, Mehra R, Ricketts CJ, Ding L, Chinnaiyan AM, Cieslik MP, Dhanasekaran SM, Zhang H, Nesvizhskii AI; Clinical Proteomic Tumor Analysis Consortium. Comprehensive proteogenomic characterization of rare kidney tumors. Cell Rep Med. 2024 May 21;5(5):101547. doi: 10.1016/j.xcrm.2024.101547. Epub 2024 May 3. PMID: 38703764; PMCID: PMC11148773.
Michigan Medicine press release
Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA Oncol. 2024 Jun 1;10(6):726-736. doi: 10.1001/jamaoncol.2024.0455. PMID: 38635241; PMCID: PMC11190811.
Michigan Medicine press release
He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Vaishampayan U, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2322563121. doi: 10.1073/pnas.2322563121. Epub 2024 Apr 1. PMID: 38557192; PMCID: PMC11009648.
Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, Wang Y, Bai L, McEachern D, Luo J, Wang M, Li Q, Matvekas A, Wen B, Sun D, Chinnaiyan AM, Wang S. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. J Med Chem. 2024 Apr 11;67(7):5351-5372. doi: 10.1021/acs.jmedchem.3c01789. Epub 2024 Mar 26. PMID: 38530938.